NEW YORK, July 6, 2026 /PRNewswire/ — Nuvation Bio Inc. (“Nuvation Bio”) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the…
Source: prnewswire
Country: United States